Molecular Imaging: Page 106

Anavex wins $1M grant for PET research

By AuntMinnie.com staff writers

Biopharmaceutical firm Anavex Life Sciences has received a nearly $1 million grant from the Michael J. Fox Foundation to investigate using PET imaging biomarkers to assess its Anavex 2-73 drug for treating Parkinson's disease.

January 11, 2021

ARTMS, Telix produce PSMA-11 in cyclotron

By AuntMinnie.com staff writers

ARTMS and Telix Pharmaceuticals this week announced a milestone in their relationship to produce a prostate-specific membrane antigen (PSMA)-11-based radiopharmaceutical using cyclotrons.

January 11, 2021

Could AI lower malpractice risk for physicians?

By Erik L. Ridley

Although some legal scholars believe that liability concerns could hinder adoption of artificial intelligence (AI) software in personalized medicine, a new study published in the Journal of Nuclear Medicine found that physicians who follow the technology's advice may actually be shielded from malpractice liability.

January 11, 2021

Is there a place for whole-body cancer screening?

By Kate Madden Yee

A whole-body imaging cancer screening program could be an effective way to detect early-stage cancer among a motivated screening population, according to a study from Japan published January 1 in the Journal of the American College of Radiology.

January 11, 2021

ImaginAb, Pfizer ink deal on PET agent

By AuntMinnie.com staff writers

Imaging agent developer ImaginAb signed a multiyear, nonexclusive license with Pfizer to supply the zirconium-89 CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.

January 7, 2021

Avacta inks license agreement with Point Biopharma

By AuntMinnie.com staff writers

Avacta Group has signed a license agreement with Point Biopharma to provide that company with access to its pre/Cision technology for developing tumor-activated radiopharmaceuticals.

January 6, 2021

NorthStar gets FDA nod to produce Mo-99 from cMo-98

By AuntMinnie.com staff writers

NorthStar Medical Radioisotopes has received U.S. Food and Drug Administration (FDA) approval to produce molybdenum-99 (Mo-99) from concentrated molybdenum-98 (cMo-98).

January 5, 2021

Blue Earth buys therapeutic rights to rhPSMA technology

By AuntMinnie.com staff writers

Bracco molecular imaging subsidiary Blue Earth Diagnostics has acquired exclusive, worldwide rights to therapeutic applications of radiohybrid prostate-specific membrane antigen (rhPSMA) technology developed by German radiopharmaceutical firm Scintomics and the Technical University of Munich.

January 4, 2021

SmartBreast acquires molecular breast tech from Dilon

By AuntMinnie.com staff writers

Private breast cancer screening firm SmartBreast has acquired molecular breast imaging technologies and patents from developer Dilon Diagnostics.

January 3, 2021

Report: COVID-19 causing radioisotope delays

By AuntMinnie.com staff writers

A drop in the volume of passenger airline travel is causing delays in the shipment of medical radioisotopes from sources in Canada, according to a January 3 report by Reuters.

January 3, 2021

ARTMS Tc-99m gets green light from Health Canada

By AuntMinnie.com staff writers

Medical isotope developer ARTMS of British Columbia, Canada, announced that its cyclotron-produced technetium-99m (Tc-99m) radioisotope is being shipped commercially following approval on November 26 for clinical use by Health Canada.

December 21, 2020

Copper radiotracers ID tumors, improve survival

By Rebekah Moan

Two copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors can not only identify tumors but also improve survival, according to new research published in the December issue of the Journal of Nuclear Medicine.

December 20, 2020

Previous Page

Page 106 of 614

Next Page